JP2006524699A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006524699A5 JP2006524699A5 JP2006513242A JP2006513242A JP2006524699A5 JP 2006524699 A5 JP2006524699 A5 JP 2006524699A5 JP 2006513242 A JP2006513242 A JP 2006513242A JP 2006513242 A JP2006513242 A JP 2006513242A JP 2006524699 A5 JP2006524699 A5 JP 2006524699A5
- Authority
- JP
- Japan
- Prior art keywords
- diuretic
- combination
- metabolite
- prodrug
- amide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000001882 diuretic effect Effects 0.000 claims 104
- 239000002934 diuretic Substances 0.000 claims 100
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims 50
- 150000001408 amides Chemical class 0.000 claims 37
- 150000002148 esters Chemical class 0.000 claims 37
- 239000002207 metabolite Substances 0.000 claims 37
- 239000000651 prodrug Substances 0.000 claims 37
- 229940002612 prodrug Drugs 0.000 claims 37
- 150000003839 salts Chemical class 0.000 claims 37
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims 28
- 239000003814 drug Substances 0.000 claims 28
- 229940109239 creatinine Drugs 0.000 claims 25
- 229940079593 drug Drugs 0.000 claims 19
- 239000003795 chemical substances by application Substances 0.000 claims 18
- 230000003907 kidney function Effects 0.000 claims 17
- 230000008327 renal blood flow Effects 0.000 claims 15
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims 14
- 229960005305 adenosine Drugs 0.000 claims 14
- 239000002171 loop diuretic Substances 0.000 claims 12
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 11
- 230000001939 inductive effect Effects 0.000 claims 9
- 208000017169 kidney disease Diseases 0.000 claims 9
- 210000002966 serum Anatomy 0.000 claims 8
- 229940030606 diuretics Drugs 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- FNYLWPVRPXGIIP-UHFFFAOYSA-N Triamterene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 claims 5
- 229960002576 amiloride Drugs 0.000 claims 5
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 claims 5
- 229960002256 spironolactone Drugs 0.000 claims 5
- 239000003451 thiazide diuretic agent Substances 0.000 claims 5
- 229960001288 triamterene Drugs 0.000 claims 5
- 208000004880 Polyuria Diseases 0.000 claims 4
- 206010061481 Renal injury Diseases 0.000 claims 4
- 230000003247 decreasing effect Effects 0.000 claims 4
- 229960003883 furosemide Drugs 0.000 claims 4
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims 4
- XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 claims 3
- 238000011863 diuretic therapy Methods 0.000 claims 3
- 239000012530 fluid Substances 0.000 claims 3
- 230000001434 glomerular Effects 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- UJEWTUDSLQGTOA-UHFFFAOYSA-N Piretanide Chemical compound C=1C=CC=CC=1OC=1C(S(=O)(=O)N)=CC(C(O)=O)=CC=1N1CCCC1 UJEWTUDSLQGTOA-UHFFFAOYSA-N 0.000 claims 2
- NGBFQHCMQULJNZ-UHFFFAOYSA-N Torsemide Chemical compound CC(C)NC(=O)NS(=O)(=O)C1=CN=CC=C1NC1=CC=CC(C)=C1 NGBFQHCMQULJNZ-UHFFFAOYSA-N 0.000 claims 2
- -1 amiloride thiazide Chemical class 0.000 claims 2
- 229960004064 bumetanide Drugs 0.000 claims 2
- MAEIEVLCKWDQJH-UHFFFAOYSA-N bumetanide Chemical compound CCCCNC1=CC(C(O)=O)=CC(S(N)(=O)=O)=C1OC1=CC=CC=C1 MAEIEVLCKWDQJH-UHFFFAOYSA-N 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- 230000035619 diuresis Effects 0.000 claims 2
- AVOLMBLBETYQHX-UHFFFAOYSA-N etacrynic acid Chemical compound CCC(=C)C(=O)C1=CC=C(OCC(O)=O)C(Cl)=C1Cl AVOLMBLBETYQHX-UHFFFAOYSA-N 0.000 claims 2
- 229960003199 etacrynic acid Drugs 0.000 claims 2
- 229960001085 piretanide Drugs 0.000 claims 2
- 229960005461 torasemide Drugs 0.000 claims 2
- 206010016803 Fluid overload Diseases 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 230000035433 tubuloglomerular feedback Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46600703P | 2003-04-25 | 2003-04-25 | |
| PCT/US2004/012518 WO2004096228A1 (en) | 2003-04-25 | 2004-04-23 | Method of improved diuresis in individuals with impaired renal function |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006524699A JP2006524699A (ja) | 2006-11-02 |
| JP2006524699A5 true JP2006524699A5 (enExample) | 2006-12-14 |
Family
ID=33418325
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006513242A Withdrawn JP2006524699A (ja) | 2003-04-25 | 2004-04-23 | 腎機能障害を持つ個体における利尿改善法 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US7579331B2 (enExample) |
| EP (1) | EP1620107A1 (enExample) |
| JP (1) | JP2006524699A (enExample) |
| KR (1) | KR20060004959A (enExample) |
| CN (1) | CN1859913A (enExample) |
| AR (1) | AR044069A1 (enExample) |
| AU (1) | AU2004233852A1 (enExample) |
| BR (1) | BRPI0409699A (enExample) |
| CA (1) | CA2522971A1 (enExample) |
| MX (1) | MXPA05011371A (enExample) |
| NO (1) | NO20055536L (enExample) |
| NZ (1) | NZ543109A (enExample) |
| RU (1) | RU2367442C2 (enExample) |
| TW (1) | TW200500070A (enExample) |
| WO (1) | WO2004096228A1 (enExample) |
| ZA (1) | ZA200509311B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040229901A1 (en) * | 2003-02-24 | 2004-11-18 | Lauren Otsuki | Method of treatment of disease using an adenosine A1 receptor antagonist |
| EP1620107A1 (en) * | 2003-04-25 | 2006-02-01 | Novacardia, Inc. | Method of improved diuresis in individuals with impaired renal function |
| US20060293312A1 (en) * | 2003-04-25 | 2006-12-28 | Howard Dittrich | Method of improved diuresis in individuals with impaired renal function |
| JP2007504135A (ja) * | 2003-08-28 | 2007-03-01 | ニトロメッド インコーポレーティッド | ニトロソ化およびニトロシル化心血管化合物、組成物、ならびに使用方法 |
| US20050239759A1 (en) * | 2004-04-16 | 2005-10-27 | Lauren Otsuki | Method of treatment of disease using an adenosine A1 receptor antagonist and an aldosterone inhibitor |
| EP1855688A4 (en) * | 2005-02-24 | 2011-09-14 | Nicox Sa | NON-STAINED OXIDE DIURETIC COMPOUNDS, COMPOSITIONS AND USE PROCESSES |
| CA2608111A1 (en) * | 2005-04-22 | 2006-11-02 | Novacardia, Inc. | Production of emulsions for intravenous injection of water-insoluble pharmaceutical compositions |
| EP1961422A1 (en) * | 2005-12-14 | 2008-08-27 | Kyowa Hakko Kogyo Co., Ltd. | Easily absorbed oral preparation containing xanthine derivative |
| CA2648281A1 (en) * | 2006-04-06 | 2007-10-18 | Novacardia, Inc. | Co-administration of adenosine a1 receptor antagonists and anticonvulsants |
| JP2009540003A (ja) * | 2006-06-16 | 2009-11-19 | ノヴァカーディア，インク． | Ａａ１ｒａの低頻度投与を含む腎機能の長期間にわたる改善 |
| CN101466435A (zh) * | 2006-06-16 | 2009-06-24 | 美国诺华卡迪亚公司 | Kw-3902在充血性心脏衰竭和急性体液超负荷患者中实现利尿作用的用途 |
| WO2008121882A1 (en) * | 2007-03-29 | 2008-10-09 | Novacardia, Inc. | Improved methods of administration of adenosine a1 receptor antagonists |
| WO2008121893A1 (en) * | 2007-03-29 | 2008-10-09 | Novacardia, Inc. | Methods of treating heart failure and renal dysfunction in individuals with an adenosine a1 receptor antagonist |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE416810C (sv) | 1977-10-14 | 1982-07-19 | Draco Ab | Forfarande for framstellning av xantinderivat med antiallergisk aktivitet |
| FR2531085A1 (fr) | 1982-07-28 | 1984-02-03 | Adir | Nouveaux derives de la xanthine, leur procede de preparation et les compositions pharmaceutiques les renfermant |
| US4769377A (en) | 1983-02-18 | 1988-09-06 | The Johns Hopkins University | Adenosine receptor antagonists |
| DE8817122U1 (de) | 1988-12-22 | 1993-02-04 | Boehringer Ingelheim Kg, 55218 Ingelheim | Neue Xanthinderivate mit Adenosinantogenistischer Wirkung |
| US5290782A (en) | 1989-09-01 | 1994-03-01 | Kyowa Hakko Kogyo Co., Ltd. | Xanthine derivatives |
| SE9000207L (sv) | 1990-01-22 | 1991-07-23 | Nobel Chemicals Ab | Laekemedel samt anvaendningen av detsamma |
| DE4019892A1 (de) | 1990-06-22 | 1992-01-02 | Boehringer Ingelheim Kg | Neue xanthinderivate |
| AU2297192A (en) | 1991-06-28 | 1993-01-25 | Sepracor, Inc. | Optically pure s(-) nadolol for treatment of cardiovascular disorders |
| CA2093403C (en) | 1992-04-08 | 1999-08-10 | Fumio Suzuki | Therapeutic agent for parkinson's disease |
| TW252044B (enExample) | 1992-08-10 | 1995-07-21 | Boehringer Ingelheim Kg | |
| DE4238367A1 (de) | 1992-11-13 | 1994-05-19 | Boehringer Ingelheim Kg | Diuretisches Mittel |
| US5395836A (en) | 1993-04-07 | 1995-03-07 | Kyowa Hakko Kogyo Co., Ltd. | 8-tricycloalkyl xanthine derivatives |
| US5736528A (en) | 1993-10-28 | 1998-04-07 | University Of Florida Research Foundation, Inc. | N6 -(epoxynorborn-2-yl) adenosines as A1 adenosine receptor agonists |
| US5446046A (en) | 1993-10-28 | 1995-08-29 | University Of Florida Research Foundation | A1 adenosine receptor agonists and antagonists as diuretics |
| CN1049117C (zh) | 1994-09-16 | 2000-02-09 | 赵明玉 | 预防和治疗偏头痛的偏头痛片 |
| ES2199289T3 (es) | 1995-07-26 | 2004-02-16 | Kyowa Hakko Kogyo Co., Ltd. | Dispersion solida de derivados de xantina. |
| ATE281835T1 (de) | 1996-08-07 | 2004-11-15 | Kyowa Hakko Kogyo Kk | Fettemulsion, die ein xanthinderivat enthält |
| US6187780B1 (en) | 1998-04-16 | 2001-02-13 | Boehringer Ingelheim Pharma Kg | Assymetrically substituted xanthine derivatives having adenosine A1 antagonistic activity |
| DE19816857A1 (de) | 1998-04-16 | 1999-10-21 | Boehringer Ingelheim Pharma | Neue unsymmetrisch substituierte Xanthin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| DE69912375T2 (de) | 1998-04-24 | 2004-08-19 | Cv Therapeutics, Palo Alto | Adenosin a1 rezeptor antagonisten enthaltende zusammensetzung und verfahren zur wiederherstellung der diuretischen- und nierenfunktion |
| US20020115687A1 (en) | 1998-04-24 | 2002-08-22 | Evan Beckman | Method and composition for restoring diuretic and renal function |
| EP0970696A1 (en) | 1998-05-05 | 2000-01-12 | Kyowa Hakko Kogyo Co., Ltd. | Combination of loop diuretics with adenosine A1-receptor antagonists |
| UA74141C2 (uk) | 1998-12-09 | 2005-11-15 | Дж.Д. Сірл Енд Ко. | Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти) |
| SE9903028D0 (sv) | 1999-08-27 | 1999-08-27 | Astra Ab | New use |
| CA2390590C (en) | 1999-11-12 | 2010-03-16 | Biogen, Inc. | Adenosine receptor antagonists and methods of making and using the same |
| EP2305684A1 (en) | 1999-11-12 | 2011-04-06 | Biogen Idec MA Inc. | Poycyloalkylpurines as adenosine receptor antagonists |
| US20050038017A1 (en) | 1999-12-22 | 2005-02-17 | Wolff Andrew A. | Method and composition for restoring diuretic and renal function |
| YU42903A (sh) | 2000-12-01 | 2006-05-25 | Biogen Inc. | Kondenzovani derivati purina kao antagonisti a1 receptora adenozina |
| JP2004516266A (ja) | 2000-12-18 | 2004-06-03 | ノバルティス アクチエンゲゼルシャフト | アムロジピンおよびベナゼブリルの治療的組み合わせ |
| UA80258C2 (en) | 2001-09-06 | 2007-09-10 | Biogen Inc | Methods of treating pulmonary disease |
| US20040229901A1 (en) | 2003-02-24 | 2004-11-18 | Lauren Otsuki | Method of treatment of disease using an adenosine A1 receptor antagonist |
| EP1620107A1 (en) | 2003-04-25 | 2006-02-01 | Novacardia, Inc. | Method of improved diuresis in individuals with impaired renal function |
| US20060293312A1 (en) | 2003-04-25 | 2006-12-28 | Howard Dittrich | Method of improved diuresis in individuals with impaired renal function |
| WO2005000294A1 (en) | 2003-06-06 | 2005-01-06 | Pharmacia Corporation | Selective inhibitor and an anticonvulsant agent for the treatment of central nervous system disorders |
| US20050239759A1 (en) | 2004-04-16 | 2005-10-27 | Lauren Otsuki | Method of treatment of disease using an adenosine A1 receptor antagonist and an aldosterone inhibitor |
| JP2007535560A (ja) | 2004-04-28 | 2007-12-06 | シーブイ・セラピューティクス・インコーポレイテッド | Ａ１アデノシンレセプターアンタゴニスト |
| CA2648281A1 (en) | 2006-04-06 | 2007-10-18 | Novacardia, Inc. | Co-administration of adenosine a1 receptor antagonists and anticonvulsants |
| CN101466435A (zh) | 2006-06-16 | 2009-06-24 | 美国诺华卡迪亚公司 | Kw-3902在充血性心脏衰竭和急性体液超负荷患者中实现利尿作用的用途 |
| JP2009540003A (ja) | 2006-06-16 | 2009-11-19 | ノヴァカーディア，インク． | Ａａ１ｒａの低頻度投与を含む腎機能の長期間にわたる改善 |
| EP2061793A2 (en) | 2006-08-22 | 2009-05-27 | Novacardia, Inc. | Kw-3902 conjugates that do not cross the blood-brain barrier |
-
2004
- 2004-04-23 EP EP04760339A patent/EP1620107A1/en not_active Withdrawn
- 2004-04-23 CA CA002522971A patent/CA2522971A1/en not_active Abandoned
- 2004-04-23 JP JP2006513242A patent/JP2006524699A/ja not_active Withdrawn
- 2004-04-23 NZ NZ543109A patent/NZ543109A/en unknown
- 2004-04-23 WO PCT/US2004/012518 patent/WO2004096228A1/en not_active Ceased
- 2004-04-23 RU RU2005131938/15A patent/RU2367442C2/ru not_active IP Right Cessation
- 2004-04-23 CN CNA2004800105597A patent/CN1859913A/zh active Pending
- 2004-04-23 AU AU2004233852A patent/AU2004233852A1/en not_active Abandoned
- 2004-04-23 MX MXPA05011371A patent/MXPA05011371A/es not_active Application Discontinuation
- 2004-04-23 KR KR1020057020243A patent/KR20060004959A/ko not_active Ceased
- 2004-04-23 US US10/830,617 patent/US7579331B2/en not_active Expired - Fee Related
- 2004-04-23 AR ARP040101381A patent/AR044069A1/es unknown
- 2004-04-23 BR BRPI0409699-1A patent/BRPI0409699A/pt not_active IP Right Cessation
- 2004-04-23 TW TW093111522A patent/TW200500070A/zh unknown
-
2005
- 2005-10-11 US US11/248,479 patent/US20060030572A1/en not_active Abandoned
- 2005-10-11 US US11/248,905 patent/US20060035911A1/en not_active Abandoned
- 2005-11-17 ZA ZA200509311A patent/ZA200509311B/en unknown
- 2005-11-23 NO NO20055536A patent/NO20055536L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Fogel et al. | Diuresis in the ascitic patient: a randomized controlled trial of three regimens | |
| JP2022009125A5 (enExample) | ||
| JP2006524699A5 (enExample) | ||
| JP2020508339A5 (enExample) | ||
| JP6353577B2 (ja) | 組み合わせ組成物 | |
| Kim et al. | Ethacrynic acid and furosemide: Diuretic and hemodynamic effects and clinical uses | |
| JP2002522485A5 (enExample) | ||
| HRP20210294T1 (hr) | Postupci liječenja akutnog bubrežnog oštećenja | |
| JP2002528502A5 (enExample) | ||
| Cruz et al. | Intradialytic hypotension: Is midodrine beneficial in symptomatic hemodialysis patients? | |
| JP2019533660A5 (enExample) | ||
| JP2018531929A5 (enExample) | ||
| JP2017514911A5 (enExample) | ||
| JP2008509224A5 (enExample) | ||
| HRP20221185T1 (hr) | Beta-ukosnica peptidomimetik s inhibitorskom aktivnošću elastase i njegovi oblici doziranja aerosolom | |
| JP2020500864A5 (enExample) | ||
| JP2020510043A5 (enExample) | ||
| CN110974828A (zh) | 化合物Axitinib在制备治疗脑血管疾病的药物中的应用及其药物组合物 | |
| RU2005131938A (ru) | Способ нормализации мочеиспускания при нарушении функции почек | |
| SHAFAT et al. | Reversal of cardiovascular toxicity in severe organophosphate poisoning with 20% Intralipid emulsion therapy: case report and review of literature | |
| JP2019509309A5 (enExample) | ||
| RS64668B1 (sr) | Montelukast za lečenje erozivnog osteoartritisa šake | |
| JP2009506088A (ja) | チアジド系利尿薬とループ利尿薬との組合せ調製物 | |
| RU2005131943A (ru) | Лечебные и/или профилактические средства для хронических болезней кожи | |
| Ramanathan | Pharmacology review: bronchopulmonary dysplasia and diuretics |